Clinical trials: gemcitabine hydrochloride
Unspecified Adult Solid Tumor, Protocol Specific
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004144
- Testing
- bryostatin 1, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Lung cancer is a leading cause of cancer-related death worldwide. Interstitial Lung Diseases are closely associated with lung cancer either as complications or comorbidities to be considered for treatment.
- Trial name
- NCT07420439
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 31 sites in France
- Volunteers
- 108 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Biliary Tract Cancer
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed…
- Trial name
- NCT05065957
- Testing
- D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX
- Where
- 5 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- InnoPharmax Inc.
Nonsmall Cell Lung Cancer, EGFR Gene Mutation
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations.
- Trial name
- NCT03002844
- Testing
- EGFR-TK Inhibitor, EGFR-TKI, EGFR-TKI and Chemotherapy
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC).
- Conditions
- Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06064097
- Testing
- Biopsy Procedure, Biospecimen Collection, Chest Radiography
- Where
- 86 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma of the Bile Duct
Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma
The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA
- Trial name
- NCT04305288
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Recurrent or Metastatic Cervical Cancer
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
This is a randomized, open-label, 3-arm Phase 2 study to evaluate the efficacy and safety of SHR-1210 alone or with SHR-1020 versus physician's choice chemotherapy in recurrent or metastatic cervical cancer patients.
- Trial name
- NCT04680988
- Testing
- SHR-1210, SHR-1020, Physician's choice chemotherapy
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT06492915
- Testing
- Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Hodgkin's Lymphoma
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify…
- Trial name
- IIL-ProHLRec (NCT01478191)
- Where
- 40 sites in Italy
- Volunteers
- 495 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Neuroendocrine Tumors
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a…
- Trial name
- MGMT-NET (NCT03217097)
- Testing
- Oxaliplatin-based chemotherapy, Alkylating-based chemotherapy
- Where
- 19 sites in France
- Volunteers
- 116 people
- Sponsor
- Hospices Civils de Lyon
Non-Small-Cell Lung Carcinoma
Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.
The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.
- Trial name
- NCT00191620
- Testing
- Gemcitabine, cisplatin
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer
- Trial name
- RIGHT Choice (NCT03839823)
- Testing
- Docetaxel / Capecitabine, Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine
- Where
- 50 sites in Egypt, India and 11 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Random Trial for Elderly Patients With NSCLC
1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy. 2.
- Trial name
- NCT00265694
- Testing
- vinorelbine, gemcitabine and carboplatin
- Where
- South Korea
- Sponsor
- Inje University
Adenocarcinoma of Colon, Adenocarcinoma of Rectum
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of…
- Conditions
- Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
- Trial name
- NCT01703910
- Testing
- Arm A chemotherapy, arm B chemotherapy
- Where
- 2 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
ALPACA is an interventional, multicentre, open-label, randomized active-controlled phase II trial with two arms. To estimate the treatment effect on overall survival, feasibility, efficacy and safety of alternating treatment…
- Trial name
- ALPACA (NCT02564146)
- Testing
- nab-paclitaxel and gemcitabine, gemcitabine mono and nab-paclitaxel and gemcitabine
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- AIO-Studien-gGmbH
Pancreatic Cancer
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic…
- Trial name
- NCT01025570
- Testing
- Gemcitabine, Bosutinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00425841
- Testing
- gemcitabine hydrochloride, oxaliplatin, adjuvant therapy
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Technical University of Munich
Nasopharyngeal Carcinoma
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable efficacy and a favourable toxicity profile…
- Trial name
- NCT00697905
- Testing
- Gemcitabine, Carboplatin, Cisplatin
- Where
- 11 sites in Malaysia
- Volunteers
- 18 people
- Sponsor
- Ministry of Health, Malaysia
T-cell Non-Hodgkin Lymphoma
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
The current standard of care for the frontline treatment of peripheral T-cell lymphomas (PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT).
- Trial name
- NCT01746173
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.